Back HIV Treatment Approved HIV Drugs

Approved HIV Drugs

AIDS 2012: Changing Epidemiology of Opportunistic Infections in the ART Era

Large overall declines in opportunistic infections (OIs) among people with HIV in the U.S. mask continued high rates among inner city populations, according to a presentation Monday at the XIX International AIDS Conference (AIDS 2012) in Washington, DC.alt

Read more:

NRTI-sparing Atazanavir + Raltegravir: Conflicting Data for Naive and Experienced HIV Patients

A NRTI-sparing antiretroviral regimen of unboosted atazanavir (Reyataz) plus raltegravir (Isentress) suppresses HIV in treatment-naive patients as well as standard 3-drug combinations, but its twice-daily dosing, side effects, and low barrier to resistance limit its appeal. For treatment-experienced people already doing well on atazanavir triple therapy, however, the dual regimen may be an attractive simplification option.

Read more:

FDA Approves New Fosamprenavir Dose Regimen, Nevirapine Tablets for HIV+ Children

The U.S. Food and Drug Administration (FDA) has approved new dosing recommendations for use of fosamprenavir (Lexiva) oral suspension for children with HIV. The agency also approved a generic nevirapine tablet for use by HIV positive children in PEPFAR countries.alt

Read more:

Raltegravir Shows Long-term Treatment Benefit, Appears Useful for Post-Exposure Prevention

The U.S. Food and Drug Administration (FDA) recently approved new product label information for raltegravir (Isentress), adding longer-term data showing that the drug remains effective for more than 3 years. In related news, researchers reported that raltegravir appears to be a good option for post-exposure prophylaxis (PEP) to prevent HIV infection.alt

Read more:

Raltegravir (Isentress) Label Updated with New Side Effects Warning

The U.S. Food and Drug Administration (FDA) this week announced that the product information for the integrase inhibitor raltegravir (brand name Isentress) has been revised to include new warnings about potential skin reactions and other adverse events.alt

Read more: